Pfizer's Xyntha-administering syringe gets FDA approval

NEW YORK The Food and Drug Administration has approved a prefilled dual-chamber syringe made by Pfizer for treating hemophilia, Pfizer said.

The FDA approved the syringe for administering the drug Xyntha (antihemophilic factor [recombinant]) for hemophilia A. The drug is used to prevent and control bleeding episodes in patients.

“The approval of the pre-filled dual-chamber syringe is an important milestone for hemophilia patients due to its innovative, convenient reconstitution system that eliminates the transfer step,” Pfizer VP marketing for specialty biologics Emil Andrusko said.

Login or Register to post a comment.